Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

STING pathway agonism as a cancer therapeutic.

Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF.

Immunol Rev. 2019 Jul;290(1):24-38. doi: 10.1111/imr.12765. Review.

PMID:
31355488
2.

A Longitudinal Study of Ebola Sequelae in Liberia.

PREVAIL III Study Group, Sneller MC, Reilly C, Badio M, Bishop RJ, Eghrari AO, Moses SJ, Johnson KL, Gayedyu-Dennis D, Hensley LE, Higgs ES, Nath A, Tuznik K, Varughese J, Jensen KS, Dighero-Kemp B, Neaton JD, Lane HC, Fallah MP.

N Engl J Med. 2019 Mar 7;380(10):924-934. doi: 10.1056/NEJMoa1805435.

3.

PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.

Bolay FK, Grandits G, Lane HC, Kennedy SB, Johnson MP, Fallah MP, Wilson B, Njoh WS, McNay LA, Hensley LE, Higgs ES.

J Infect Dis. 2019 Apr 19;219(10):1634-1641. doi: 10.1093/infdis/jiy698.

4.

The Effects of Oxygenation on Ex Vivo Kidneys Undergoing Hypothermic Machine Perfusion.

Patel K, Smith TB, Neil DAH, Thakker A, Tsuchiya Y, Higgs EB, Hodges NJ, Ready AR, Nath J, Ludwig C.

Transplantation. 2019 Feb;103(2):314-322. doi: 10.1097/TP.0000000000002542.

PMID:
30461718
5.

Clinical research networks are key to accurate and timely assessment of pandemic clinical severity.

Simonsen L, Higgs E, Taylor RJ.

Lancet Glob Health. 2018 Sep;6(9):e956-e957. doi: 10.1016/S2214-109X(18)30304-8. No abstract available.

6.

Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report.

Dokubo EK, Wendland A, Mate SE, Ladner JT, Hamblion EL, Raftery P, Blackley DJ, Laney AS, Mahmoud N, Wayne-Davies G, Hensley L, Stavale E, Fakoli L, Gregory C, Chen TH, Koryon A, Roth Allen D, Mann J, Hickey A, Saindon J, Badini M, Baller A, Clement P, Bolay F, Wapoe Y, Wiley MR, Logue J, Dighero-Kemp B, Higgs E, Gasasira A, Williams DE, Dahn B, Kateh F, Nyenswah T, Palacios G, Fallah MP.

Lancet Infect Dis. 2018 Sep;18(9):1015-1024. doi: 10.1016/S1473-3099(18)30417-1. Epub 2018 Jul 23.

PMID:
30049622
7.

The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection.

Davey RT Jr, Dodd L, Proschan M, Jahrling P, Hensley L, Higgs E, Lane HC.

J Infect Dis. 2018 Nov 22;218(suppl_5):S690-S697. doi: 10.1093/infdis/jiy334.

PMID:
30032267
8.

Doing What We Do, Better: Improving Our Work Through Systematic Program Reporting.

Koek I, Monclair M, Anastasi E, Ten Hoope-Bender P, Higgs E, Obregon R.

Glob Health Sci Pract. 2018 Jun 29;6(2):257-259. doi: 10.9745/GHSP-D-18-00136. Print 2018 Jun 27. No abstract available.

9.

UK birth registration and its present discontents.

Higgs E.

Reprod Biomed Soc Online. 2017 Dec 27;5:35-37. doi: 10.1016/j.rbms.2017.11.001. eCollection 2018 Apr.

10.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic.

Simonsen L, Higgs E, Taylor RJ, Wentworth D, Cozzi-Lepri A, Pett S, Dwyer DE, Davey R, Lynfield R, Losso M, Morales K, Glesby MJ, Weckx J, Carey D, Lane C, Lundgren J; INSIGHT FLU002 and FLU003 Study Groups.

Clin Infect Dis. 2018 Jul 18;67(3):341-349. doi: 10.1093/cid/ciy088.

11.

Keep ecological restoration open and flexible.

Higgs ES, Harris JA, Heger T, Hobbs RJ, Murphy SD, Suding KN.

Nat Ecol Evol. 2018 Apr;2(4):580. doi: 10.1038/s41559-018-0483-9. No abstract available.

PMID:
29403073
12.

A criteria and indicators monitoring framework for food forestry embedded in the principles of ecological restoration.

Park H, Higgs E.

Environ Monit Assess. 2018 Feb 2;190(3):113. doi: 10.1007/s10661-018-6494-9.

PMID:
29396659
13.

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.

Gsell PS, Camacho A, Kucharski AJ, Watson CH, Bagayoko A, Nadlaou SD, Dean NE, Diallo A, Diallo A, Honora DA, Doumbia M, Enwere G, Higgs ES, Mauget T, Mory D, Riveros X, Oumar FT, Fallah M, Toure A, Vicari AS, Longini IM, Edmunds WJ, Henao-Restrepo AM, Kieny MP, Kéïta S.

Lancet Infect Dis. 2017 Dec;17(12):1276-1284. doi: 10.1016/S1473-3099(17)30541-8. Epub 2017 Oct 9. Erratum in: Lancet Infect Dis. 2017 Dec;17 (12 ):1232.

14.

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, Gupta S, Hensley L, Higgs E, Janosko K, Johnson M, Kateh F, Logue J, Marchand J, Monath T, Nason M, Nyenswah T, Roman F, Stavale E, Wolfson J, Neaton JD, Lane HC; PREVAIL I Study Group.

N Engl J Med. 2017 Oct 12;377(15):1438-1447. doi: 10.1056/NEJMoa1614067.

15.

Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.

Higgs ES, Dubey SA, Coller BAG, Simon JK, Bollinger L, Sorenson RA, Wilson B, Nason MC, Hensley LE.

Curr Top Microbiol Immunol. 2017;411:229-261. doi: 10.1007/82_2017_53. Review.

PMID:
28918539
16.

Toward principles of historical ecology.

Beller E, McClenachan L, Trant A, Sanderson EW, Rhemtulla J, Guerrini A, Grossinger R, Higgs E.

Am J Bot. 2017 May;104(5):645-648. doi: 10.3732/ajb.1700070. Epub 2017 May 17. No abstract available.

17.

Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.

Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, Hamilton A, Ananda S, Lindeman GJ, Scott CL.

Gynecol Oncol. 2017 Apr;145(1):130-136. doi: 10.1016/j.ygyno.2017.01.030. Epub 2017 Feb 3.

PMID:
28162234
18.

Assessment and Optimization of the GeneXpert Diagnostic Platform for Detection of Ebola Virus RNA in Seminal Fluid.

Pettitt J, Higgs E, Fallah M, Nason M, Stavale E, Marchand J, Reilly C, Jensen K, Dighero-Kemp B, Tuznik K, Logue J, Bolay F, Hensley L.

J Infect Dis. 2017 Feb 15;215(4):547-553. doi: 10.1093/infdis/jiw599.

19.

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.

Oncotarget. 2016 Dec 13;7(50):81995-82012. doi: 10.18632/oncotarget.13226.

20.

Pregnancy outcomes in Liberian women who conceived after recovery from Ebola virus disease.

Fallah MP, Skrip LA, Dahn BT, Nyenswah TG, Flumo H, Glayweon M, Lorseh TL, Kaler SG, Higgs ES, Galvani AP.

Lancet Glob Health. 2016 Oct;4(10):e678-9. doi: 10.1016/S2214-109X(16)30147-4. No abstract available.

21.

'A short time but a lovely little short time': Bereaved parents' experiences of having a child with spinal muscular atrophy type 1.

Higgs EJ, McClaren BJ, Sahhar MA, Ryan MM, Forbes R.

J Paediatr Child Health. 2016 Jan;52(1):40-6. doi: 10.1111/jpc.12993. Epub 2015 Sep 10.

PMID:
26437687
22.

Use of Existing Diagnostic Reverse-Transcription Polymerase Chain Reaction Assays for Detection of Ebola Virus RNA in Semen.

Pettitt J, Higgs ES, Adams RD, Jahrling PB, Hensley LE.

J Infect Dis. 2016 Apr 15;213(8):1237-9. doi: 10.1093/infdis/jiv454. Epub 2015 Sep 15.

23.

Conservation. Committing to ecological restoration.

Suding K, Higgs E, Palmer M, Callicott JB, Anderson CB, Baker M, Gutrich JJ, Hondula KL, LaFevor MC, Larson BM, Randall A, Ruhl JB, Schwartz KZ.

Science. 2015 May 8;348(6235):638-40. doi: 10.1126/science.aaa4216. No abstract available.

PMID:
25953995
24.

Radial versus femoral access for cardiac catheterisation: impact on quality of life.

Yuan DZ, Brooks M, Dabin B, Higgs E, Hyun K, Brieger D.

Int J Cardiol. 2015 Jan 15;178:91-2. doi: 10.1016/j.ijcard.2014.10.159. Epub 2014 Oct 25. No abstract available.

PMID:
25464227
25.

Novel ecosystems: concept or inconvenient reality? A response to Murcia et al.

Hobbs RJ, Higgs ES, Harris JA.

Trends Ecol Evol. 2014 Dec;29(12):645-6. doi: 10.1016/j.tree.2014.09.006. Epub 2014 Oct 13. No abstract available.

PMID:
25439734
26.

Understanding the role of mHealth and other media interventions for behavior change to enhance child survival and development in low- and middle-income countries: an evidence review.

Higgs ES, Goldberg AB, Labrique AB, Cook SH, Schmid C, Cole CF, Obregón RA.

J Health Commun. 2014;19 Suppl 1:164-89. doi: 10.1080/10810730.2014.929763. Review.

27.

Protections for clinical trials in low and middle income countries need strengthening not weakening.

Dal-Ré R, Ndebele P, Higgs E, Sewankambo N, Wendler D.

BMJ. 2014 Jul 4;349:g4254. doi: 10.1136/bmj.g4254. No abstract available. Erratum in: BMJ. 2014;349:g4516.

28.

A taxonomy and results from a comprehensive review of 28 maternal health voucher programmes.

Bellows BW, Conlon CM, Higgs ES, Townsend JW, Nahed MG, Cavanaugh K, Grainger CG, Okal J, Gorter AC.

J Health Popul Nutr. 2013 Dec;31(4 Suppl 2):106-28. Review.

PMID:
24992806
29.

Evidence acquisition and evaluation for evidence summit on enhancing provision and use of maternal health services through financial incentives.

Higgs ES, Stammer E, Roth R, Balster RL.

J Health Popul Nutr. 2013 Dec;31(4 Suppl 2):23-35. Review.

PMID:
24992801
30.

Financial incentives and maternal health: where do we go from here?

Morgan L, Stanton ME, Higgs ES, Balster RL, Bellows BW, Brandes N, Comfort AB, Eichler R, Glassman A, Hatt LE, Conlon CM, Koblinsky M.

J Health Popul Nutr. 2013 Dec;31(4 Suppl 2):8-22. Review.

PMID:
24992800
31.

Investigating financial incentives for maternal health: an introduction.

Stanton ME, Higgs ES, Koblinsky M.

J Health Popul Nutr. 2013 Dec;31(4 Suppl 2):1-7. Review.

PMID:
24992799
32.

Evidence acquisition and evaluation for a U.S. Government Evidence Summit on Protecting Children Outside Family Care.

Higgs ES, Zlidar VM, Balster RL.

Child Abuse Negl. 2012 Oct;36(10):689-700. doi: 10.1016/j.chiabu.2012.09.002. Epub 2012 Oct 18. Review.

PMID:
23083899
33.

Fulfilling the metabolic requirements for cell proliferation.

Moncada S, Higgs EA, Colombo SL.

Biochem J. 2012 Aug 15;446(1):1-7. doi: 10.1042/BJ20120427. Review.

PMID:
22835215
34.

Neurocysticercosis: neglected but not forgotten.

Coyle CM, Mahanty S, Zunt JR, Wallin MT, Cantey PT, White AC Jr, O'Neal SE, Serpa JA, Southern PM, Wilkins P, McCarthy AE, Higgs ES, Nash TE.

PLoS Negl Trop Dis. 2012;6(5):e1500. doi: 10.1371/journal.pntd.0001500. Epub 2012 May 29. Review. No abstract available.

35.

Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States.

Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR 3rd, Higgs E, Randolph AG, Smoot BE, Thompson BT; NHLBI ARDS Network.

Crit Care Med. 2012 May;40(5):1487-98. doi: 10.1097/CCM.0b013e3182416f23.

36.

Fingerprints and citizenship: the British state and the identification of pensioners in the interwar period.

Higgs E.

Hist Workshop J. 2010 Spring;(69):52-67. No abstract available.

PMID:
20514737
37.

End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease.

Ison MG, de Jong MD, Gilligan KJ, Higgs ES, Pavia AT, Pierson J, Hayden FG.

J Infect Dis. 2010 Jun 1;201(11):1654-62. doi: 10.1086/652498. Review.

PMID:
20423224
38.

Novel ecosystems: implications for conservation and restoration.

Hobbs RJ, Higgs E, Harris JA.

Trends Ecol Evol. 2009 Nov;24(11):599-605. doi: 10.1016/j.tree.2009.05.012. Epub 2009 Aug 14.

PMID:
19683830
39.

The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor.

Higgs ES, Hayden FG, Chotpitayasunondh T, Whitworth J, Farrar J.

Antiviral Res. 2008 Apr;78(1):64-8. doi: 10.1016/j.antiviral.2007.10.008. Epub 2007 Nov 20.

PMID:
18295355
40.
41.

Nitric oxide and the vascular endothelium.

Moncada S, Higgs EA.

Handb Exp Pharmacol. 2006;(176 Pt 1):213-54. Review.

PMID:
16999221
42.

The discovery of nitric oxide and its role in vascular biology.

Moncada S, Higgs EA.

Br J Pharmacol. 2006 Jan;147 Suppl 1:S193-201.

43.

Plasmodium vivax vaccine research: steps in the right direction.

Higgs ES, Sina B.

Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):1-2. No abstract available.

PMID:
16291759
44.

Outcome measurement in pharmacological trials: validity of the Routine Assessment of Patient Progress (RAPP).

Ehmann TS, Kragelj T, Smith GN, Higgs E, Flynn SW, Altman S, MacEwan GW, Honer WG.

J Psychopharmacol. 2003 Dec;17(4):425-9.

PMID:
14870955
45.

ChlVPP chemotherapy in children with stage IV Hodgkin's disease: results of the UKCCSG HD 8201 and HD 9201 studies.

Atra A, Higgs E, Capra M, Elsworth A, Imeson J, Radford M, Hewitt M; UKCCSG/Hodgkin's Disease Group.

Br J Haematol. 2002 Dec;119(3):647-51.

PMID:
12437639
46.

Isolated parenchymal lung involvement in children with stage IV Hodgkin's disease: results of the UKCCSG HD8201 and HD9201 studies.

Atra A, Higgs E, Capra M, Elsworth A, Imeson J, Radford M, Pinkerton R, Hewitt M; United Kingdom Children Cancer Study Group (UKCCSG)/Hodgkin's Disease Group.

Br J Haematol. 2002 Nov;119(2):441-4.

PMID:
12406083
47.

The Annual report of the registrar general, 1839-1920: a textual history.

Higgs E.

Clio Med. 2002;67:55-76. No abstract available.

PMID:
12215198
48.

International research ethics: progress, but not perfection.

Jesus JE, Higgs ES.

Trends Mol Med. 2002 Feb;8(2):93-5.

PMID:
11815276
49.

Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group.

Hewitt RG, Yiannoutsos CT, Higgs ES, Carey JT, Geiseler PJ, Soave R, Rosenberg R, Vazquez GJ, Wheat LJ, Fass RJ, Antoninievic Z, Walawander AL, Flanigan TP, Bender JF.

Clin Infect Dis. 2000 Oct;31(4):1084-92. Epub 2000 Oct 25.

PMID:
11049793
50.

Supplemental Content

Support Center